Highvista Strategies LLC is an SEC-registered investment adviser based in Boston, MA that reports managing 23 hedge funds on Form ADV. It reports $9.1 billion in regulatory assets under management. Its private funds, of all types, hold $7.6 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +25.5% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +99.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $9.1 billionForm ADV Item 5.F
- Gross assets of private funds
- $7.6 billionAll private fund types, Form ADV
- Hedge funds managed
- 2340 private funds in total
- Employees
- 80Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 155759
- Latest Form ADV
- 03/31/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +22.6% | +14.8% |
| Q1 2026 | +2.4% | -4.6% |
| Q4 2025 | +27.1% | +2.4% |
| Q3 2025 | +18.7% | +7.8% |
| Q2 2025 | +11.4% | +10.4% |
| Q1 2025 | -7.6% | -4.5% |
| Q4 2024 | -4.9% | +2.1% |
| Q3 2024 | +7.7% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 136 share positions ($380,873,154) reported by HighVista Strategies LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Invesco DB Commdy Indx Trck8.97%
- Revolution Medicines Inc2.47%
- Abivax SA2.26%
- Vaxcyte Inc2.12%
- Genmab A/s2.12%
- Relay Therapeutics Inc1.94%
- Tango Therapeutics Inc1.89%
- Tarsus Pharmaceuticals Inc1.87%
- Immunovant Inc1.83%
- Cogent Biosciences Inc1.77%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Invesco DB Commdy Indx Trck | $34,169,932 | 8.97% | 1,057,238 | Unchanged |
| Revolution Medicines Inc | $9,420,818 | 2.47% | 45,897 | -31.48% |
| Abivax SA | $8,620,384 | 2.26% | 87,057 | -22.98% |
| Vaxcyte Inc | $8,085,889 | 2.12% | 142,107 | -5.10% |
| Genmab A/s | $8,066,046 | 2.12% | 226,098 | New |
| Relay Therapeutics Inc | $7,388,316 | 1.94% | 409,325 | -19.14% |
| Tango Therapeutics Inc | $7,179,836 | 1.89% | 287,769 | +10.65% |
| Tarsus Pharmaceuticals Inc | $7,108,860 | 1.87% | 90,432 | +3.87% |
| Immunovant Inc | $6,957,126 | 1.83% | 205,954 | -25.88% |
| Cogent Biosciences Inc | $6,725,962 | 1.77% | 210,055 | +11.27% |
| LB Pharmaceuticals Inc | $6,670,598 | 1.75% | 173,804 | -17.83% |
| Veradermics Inc | $6,574,545 | 1.73% | 54,232 | New |
| Edgewise Therapeutics Inc | $6,522,268 | 1.71% | 160,647 | +76.54% |
| Alkermes PLC | $6,352,037 | 1.67% | 156,763 | -12.55% |
| Compass Pathways PLC | $6,329,223 | 1.66% | 508,780 | +37.09% |
| Viridian Therapeutics Inc | $5,613,040 | 1.47% | 272,610 | +70.50% |
| Structure Therapeutics Inc | $5,321,935 | 1.40% | 170,193 | -13.24% |
| Nurix Therapeutics Inc | $5,240,527 | 1.38% | 221,026 | +8.48% |
| Nvidia Corporation | $4,999,695 | 1.31% | 21,892 | +0.46% |
| Tyra Biosciences Inc | $4,974,025 | 1.31% | 227,436 | +23.09% |
| Enliven Therapeutics Inc | $4,827,823 | 1.27% | 105,319 | -23.61% |
| Talen Energy Corp | $4,737,566 | 1.24% | 15,151 | +85.95% |
| Spyre Therapeutics Inc | $4,488,359 | 1.18% | 50,414 | -35.21% |
| Amylyx Pharmaceuticals Inc | $4,467,287 | 1.17% | 153,515 | -60.24% |
| Definium Therapeutics Inc | $4,151,813 | 1.09% | 109,086 | -55.09% |
| Amazon Com Inc | $4,047,940 | 1.06% | 16,247 | +21.27% |
| Pharvaris N V | $4,002,240 | 1.05% | 126,174 | -21.38% |
| Travere Therapeutics Inc | $3,328,957 | 0.87% | 56,538 | -34.44% |
| Vera Therapeutics Inc | $3,290,512 | 0.86% | 101,905 | -3.78% |
| Meta Platforms Inc | $3,272,012 | 0.86% | 4,512 | +288.30% |
| Micron Technology Inc | $3,254,976 | 0.85% | 3,056 | +142.54% |
| Praxis Precision Medicines I | $3,230,032 | 0.85% | 11,091 | -63.29% |
| GH Research PLC | $3,055,147 | 0.80% | 130,117 | -18.05% |
| Argenx SE | $2,994,676 | 0.79% | 3,123 | -31.53% |
| Protagonist Therapeutics Inc | $2,952,491 | 0.78% | 20,956 | -14.33% |
| Contineum Therapeutics Inc | $2,922,715 | 0.77% | 217,788 | New |
| C4 Therapeutics Inc | $2,908,012 | 0.76% | 873,277 | -35.22% |
| Union Pac Corp | $2,880,224 | 0.76% | 10,584 | New |
| Dianthus Therapeutics Inc | $2,859,864 | 0.75% | 32,480 | -36.47% |
| Insmed Inc | $2,854,299 | 0.75% | 25,007 | -19.99% |
| United Airls Hldgs Inc | $2,851,415 | 0.75% | 25,700 | New |
| Editas Medicine Inc | $2,845,319 | 0.75% | 1,107,128 | New |
| Roblox Corp | $2,762,524 | 0.73% | 65,200 | New |
| MBX Biosciences Inc | $2,738,082 | 0.72% | 46,709 | +301.49% |
| Avalo Therapeutics Inc | $2,708,397 | 0.71% | 176,673 | +44.09% |
| Cullinan Therapeutics Inc | $2,669,289 | 0.70% | 173,895 | New |
| Xenon Pharmaceuticals Inc | $2,637,069 | 0.69% | 70,908 | +100.77% |
| Ocular Therapeutix Inc | $2,579,045 | 0.68% | 336,251 | -17.69% |
| Visa Inc | $2,565,975 | 0.67% | 7,141 | +19.80% |
| Celldex Therapeutics Inc New | $2,513,201 | 0.66% | 77,544 | -10.83% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 24 new positions, 35 sold out, 47 increased, 64 reduced and 1 unchanged.
Number of positions (a count, not dollars)
- New positions24
- Increased47
- Unchanged1
- Reduced64
- Sold out35
New positions
| Stock | Value | Shares |
|---|---|---|
| Genmab A/s | $8,066,046 | 226,098 |
| Veradermics Inc | $6,574,545 | 54,232 |
| Contineum Therapeutics Inc | $2,922,715 | 217,788 |
| Union Pac Corp | $2,880,224 | 10,584 |
| United Airls Hldgs Inc | $2,851,415 | 25,700 |
| Editas Medicine Inc | $2,845,319 | 1,107,128 |
| Roblox Corp | $2,762,524 | 65,200 |
| Cullinan Therapeutics Inc | $2,669,289 | 173,895 |
| First Tracks Biotherapeutics | $2,473,216 | 69,786 |
| Flex LTD | $1,792,507 | 16,297 |
| Rivian Automotive Inc | $1,786,824 | 119,600 |
| Avantor Inc | $1,774,395 | 117,900 |
| SPS Comm Inc | $1,673,532 | 20,300 |
| Coherent Corp | $1,660,664 | 5,770 |
| Delta Air Lines Inc | $1,435,512 | 17,200 |
| Cerebras Systems Inc | $1,421,200 | 8,000 |
| National Vision Hldgs Inc | $1,369,368 | 83,600 |
| Mobility Global Inc | $1,359,686 | 79,282 |
| Alto Neuroscience Inc | $921,607 | 36,099 |
| Sea LTD | $681,520 | 7,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Alumis Inc | $5,627,100 | 199,968 |
| Mineralys Therapeutics Inc | $2,322,573 | 86,085 |
| Eyepoint Inc | $2,226,567 | 155,704 |
| RBC Bearings Inc | $2,075,805 | 3,223 |
| Rocket Cos Inc | $1,977,098 | 125,530 |
| Texas Instrs Inc | $1,937,455 | 6,500 |
| KBR Inc | $1,871,733 | 54,206 |
| Flowserve Corp | $1,850,886 | 24,958 |
| On Semiconductor Corp | $1,720,628 | 18,200 |
| Nucor Corp | $1,692,900 | 7,600 |
| Qnity Electronics Inc | $1,584,107 | 9,700 |
| Knight-swift Transn Hldgs In | $1,565,187 | 20,100 |
| Brinks Co | $1,550,959 | 16,414 |
| Qxo Inc | $1,406,938 | 81,420 |
| US Foods Hldg Corp | $1,329,250 | 13,000 |
| Lumentum Hldgs Inc | $1,301,677 | 1,517 |
| Firstenergy Corp | $1,240,794 | 26,100 |
| Moodys Corp | $1,209,296 | 2,670 |
| Applied Matls Inc | $1,185,720 | 1,640 |
| Nextera Energy Inc | $1,170,677 | 13,338 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Edgewise Therapeutics Inc | +69,651 | +76.54% | $6,522,268 | 160,647 |
| Meta Platforms Inc | +3,350 | +288.30% | $3,272,012 | 4,512 |
| Viridian Therapeutics Inc | +112,725 | +70.50% | $5,613,040 | 272,610 |
| Talen Energy Corp | +7,003 | +85.95% | $4,737,566 | 15,151 |
| MBX Biosciences Inc | +35,075 | +301.49% | $2,738,082 | 46,709 |
| Amphenol Corp | +23,749 | +410.81% | $2,489,379 | 29,530 |
| Micron Technology Inc | +1,796 | +142.54% | $3,254,976 | 3,056 |
| Compass Pathways PLC | +137,660 | +37.09% | $6,329,223 | 508,780 |
| Xenon Pharmaceuticals Inc | +35,590 | +100.77% | $2,637,069 | 70,908 |
| Vistra Corp | +9,065 | +185.00% | $1,932,058 | 13,965 |
| Credo Technology Group Holdi | +5,800 | +100.00% | $2,259,564 | 11,600 |
| Mirum Pharmaceuticals Inc | +11,768 | +79.02% | $2,278,897 | 26,660 |
| Golar LNG LTD | +21,100 | +95.48% | $2,052,864 | 43,200 |
| Immunocore Hldgs PLC | +32,655 | +75.62% | $2,297,194 | 75,840 |
| Tyra Biosciences Inc | +42,662 | +23.09% | $4,974,025 | 227,436 |
| Astera Labs Inc | +2,525 | +78.96% | $2,037,216 | 5,723 |
| Western Digital Corp | +1,906 | +62.49% | $2,252,304 | 4,956 |
| Avalo Therapeutics Inc | +54,063 | +44.09% | $2,708,397 | 176,673 |
| Mastercard Incorporated | +1,457 | +61.12% | $2,118,196 | 3,841 |
| Seagate Technology Hldngs PL | +843 | +45.08% | $2,502,308 | 2,713 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc | -232,565 | -60.24% | $4,467,287 | 153,515 |
| Praxis Precision Medicines I | -19,119 | -63.29% | $3,230,032 | 11,091 |
| Definium Therapeutics Inc | -133,798 | -55.09% | $4,151,813 | 109,086 |
| Revolution Medicines Inc | -21,086 | -31.48% | $9,420,818 | 45,897 |
| Cytokinetics Inc | -49,425 | -63.36% | $1,883,576 | 28,578 |
| Maze Therapeutics Inc | -116,979 | -85.65% | $532,538 | 19,593 |
| Abivax SA | -25,974 | -22.98% | $8,620,384 | 87,057 |
| Spyre Therapeutics Inc | -27,393 | -35.21% | $4,488,359 | 50,414 |
| Immunovant Inc | -71,919 | -25.88% | $6,957,126 | 205,954 |
| Relay Therapeutics Inc | -96,910 | -19.14% | $7,388,316 | 409,325 |
| Hewlett Packard Enterprise C | -27,370 | -46.33% | $2,026,016 | 31,711 |
| Travere Therapeutics Inc | -29,695 | -34.44% | $3,328,957 | 56,538 |
| Dyne Therapeutics Inc | -107,114 | -62.29% | $1,044,685 | 64,847 |
| Dianthus Therapeutics Inc | -18,645 | -36.47% | $2,859,864 | 32,480 |
| C4 Therapeutics Inc | -474,859 | -35.22% | $2,908,012 | 873,277 |
| Axsome Therapeutics Inc. | -8,418 | -41.71% | $2,169,349 | 11,765 |
| Enliven Therapeutics Inc | -32,547 | -23.61% | $4,827,823 | 105,319 |
| LB Pharmaceuticals Inc | -37,707 | -17.83% | $6,670,598 | 173,804 |
| Argenx SE | -1,438 | -31.53% | $2,994,676 | 3,123 |
| Liquidia Corporation | -41,219 | -42.10% | $1,715,046 | 56,677 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (9)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private equity funds filing Form D (6)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Venture capital funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (37)
As reported in the adviser's Form ADV filed Mar 28, 2024. Funds also listed from Form D are shown above.
Fund vehicles: feeder funds and single-deal vehicles (3)
Feeder funds invest through a master fund; single-deal vehicles (SPVs, co-investments, series) hold one investment.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures